These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 23157945)

  • 1. Radiotherapy for tumors of the stomach and gastroesophageal junction--a review of its role in multimodal therapy.
    Buergy D; Lohr F; Baack T; Siebenlist K; Haneder S; Michaely H; Wenz F; Boda-Heggemann J
    Radiat Oncol; 2012 Nov; 7():192. PubMed ID: 23157945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction - a randomized phase III joint study of the AIO, ARO and DGAV.
    Lorenzen S; Biederstädt A; Ronellenfitsch U; Reißfelder C; Mönig S; Wenz F; Pauligk C; Walker M; Al-Batran SE; Haller B; Hofheinz RD
    BMC Cancer; 2020 Sep; 20(1):886. PubMed ID: 32933498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Radiotherapy in cancers of the oesophagus, the gastric cardia and the stomach].
    Créhange G; Huguet F; Quero L; N'Guyen TV; Mirabel X; Lacornerie T
    Cancer Radiother; 2016 Sep; 20 Suppl():S161-8. PubMed ID: 27523409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant or neoadjuvant therapy for operable esophagogastric cancer?
    Moorcraft SY; Smyth EC; Cunningham D
    Gastric Cancer; 2015 Jan; 18(1):1-10. PubMed ID: 24638977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG).
    Leong T; Smithers BM; Michael M; Gebski V; Boussioutas A; Miller D; Simes J; Zalcberg J; Haustermans K; Lordick F; Schuhmacher C; Swallow C; Darling G; Wong R
    BMC Cancer; 2015 Jul; 15():532. PubMed ID: 26194186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preoperative and adjuvant therapies for upper gastrointestinal cancers.
    Varadhachary G; Ajani JA
    Expert Rev Anticancer Ther; 2005 Aug; 5(4):719-25. PubMed ID: 16111471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surgery and multimodal treatments in pancreatic cancer--a review on the basis of future multimodal treatment concepts.
    Link KH; Leder G; Formentini A; Fortnagel G; Kornmann M; Schatz M; Beger HG
    Gan To Kagaku Ryoho; 1999 Jan; 26(1):10-40. PubMed ID: 9987495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus.
    Ronellenfitsch U; Schwarzbach M; Hofheinz R; Kienle P; Kieser M; Slanger TE; Jensen K;
    Cochrane Database Syst Rev; 2013 May; (5):CD008107. PubMed ID: 23728671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection.
    Smalley SR; Benedetti JK; Haller DG; Hundahl SA; Estes NC; Ajani JA; Gunderson LL; Goldman B; Martenson JA; Jessup JM; Stemmermann GN; Blanke CD; Macdonald JS
    J Clin Oncol; 2012 Jul; 30(19):2327-33. PubMed ID: 22585691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Exploration and thoughts on perioperative treatment of advanced gastric cancer].
    Li YF; Zhou ZW
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):112-117. PubMed ID: 33508915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival after adjuvant chemoradiotherapy or surgery alone in resectable adenocarcinoma at the gastro-esophageal junction.
    Kofoed SC; Muhic A; Baeksgaard L; Jendresen M; Gustafsen J; Holm J; Bardram L; Brandt B; Brenø J; Svendsen LB
    Scand J Surg; 2012; 101(1):26-31. PubMed ID: 22414465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant therapy for locally advanced gastric cancer.
    Aoyama T; Yoshikawa T
    Surg Today; 2017 Nov; 47(11):1295-1302. PubMed ID: 28251375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Neoadjuvant chemoradiotherapy combined with surgery versus direct surgery in the treatment of Siewert type II and III adenocarcinomas of the esophagogastric junction: long-term prognostic analysis of a prospective randomized controlled trial].
    Tian Y; Wang Q; Wang J; Qiao XY; Zhang J; Lin YC; Li Y; Fan LQ; Yang PG; Zhao Q
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):128-137. PubMed ID: 33508918
    [No Abstract]   [Full Text] [Related]  

  • 14. Tomotherapy as an adjuvant treatment for gastroesophageal junction and stomach cancer may reduce bowel and bone marrow toxicity compared to intensity-modulated radiotherapy and volumetric-modulated arc therapy.
    Wang X; Tian Y; Tang Y; Hu ZH; Zhang JJ; Fu GS; Ma P; Ren H; Zhang T; Li N; Liu WY; Fang H; Li YX; Jin J
    Oncotarget; 2017 Jun; 8(24):39727-39735. PubMed ID: 28061474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant and neoadjuvant approaches in gastric cancer.
    Ng K; Meyerhardt JA; Fuchs CS
    Cancer J; 2007; 13(3):168-74. PubMed ID: 17620766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postoperative chemoradiotherapy combined with epirubicin-based triplet chemotherapy for locally advanced adenocarcinoma of the stomach or gastroesophageal junction.
    Li G; Zhang Z; Ma X; Zhu J; Cai G
    PLoS One; 2013; 8(1):e54233. PubMed ID: 23372688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Outcome in Patients with Carcinoma of the Esophagogastric Junction Treated with Neoadjuvant Radiochemotherapy or Perioperative Chemotherapy: A Two-Center Retrospective Analysis.
    Wundsam HV; Doleschal B; Prommer R; Venhoda C; Schmitt C; Petzer A; Metz-Gercek S; Rumpold H
    Oncology; 2020; 98(10):706-713. PubMed ID: 32516775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction - a phase III trial of the German AIO/CAO-V/CAOGI.
    Al-Batran SE; Goetze TO; Mueller DW; Vogel A; Winkler M; Lorenzen S; Novotny A; Pauligk C; Homann N; Jungbluth T; Reissfelder C; Caca K; Retter S; Horndasch E; Gumpp J; Bolling C; Fuchs KH; Blau W; Padberg W; Pohl M; Wunsch A; Michl P; Mannes F; Schwarzbach M; Schmalenberg H; Hohaus M; Scholz C; Benckert C; Knorrenschild JR; Kanngießer V; Zander T; Alakus H; Hofheinz RD; Roedel C; Shah MA; Sasako M; Lorenz D; Izbicki J; Bechstein WO; Lang H; Moenig SP
    BMC Cancer; 2017 Dec; 17(1):893. PubMed ID: 29282088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant chemoradiotherapy in gastric cancer and carcinoma of the oesophago-gastric junction.
    Stahl M
    Onkologie; 2004 Feb; 27(1):33-6. PubMed ID: 15007246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Historical evolution and research progress of perioperative therapy of locally advanced gastric cancer].
    Chen J; Ye Q; Huang F
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Feb; 22(2):196-200. PubMed ID: 30799543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.